Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. [PDF]
Mol MetabRoell W +15 more
europepmc +1 more source
Antimicrobial changes made for suspected infectious diarrhea after positive gastrointestinal pathogen panel result. [PDF]
Antimicrob Steward Healthc EpidemiolMackow NA +7 more
europepmc +1 more source
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases. [PDF]
Nephrol Dial TransplantApperloo EM +3 more
europepmc +1 more source
Critical Evaluation of "GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis". [PDF]
Clin CardiolBibi Z.
europepmc +1 more source
Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control. [PDF]
Rambam Maimonides Med JBonga KN, Padhan M.
europepmc +1 more source
The Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition. [PDF]
Int J Mol SciChrysavgis L +4 more
europepmc +1 more source
Editorial: The impact of GIP/GIPR on metabolic diseases: how the field is evolving. [PDF]
Front Endocrinol (Lausanne)Habegger K +5 more
europepmc +1 more source
GLP-1 and Dual GLP-1/GIP Receptor Agonists in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. [PDF]
Clin CardiolAhmed M +7 more
europepmc +1 more source
The Clinical Application of GLP-1RAs and GLP-1/GIP Dual Receptor Agonists Based on Pharmacological Mechanisms: A Review. [PDF]
Drug Des Devel TherLiu Z +7 more
europepmc +1 more source